RxDoctor Payments Data

Rachel Chastain

Nurse Practitioner · Green Bay, WINPI 1942661566

Payments from drug & device makers

$989in general payments, 2019–2025

Across 44 payments — averaging $22.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$264
  • Takeda Pharmaceuticals U.S.A., Inc.$162
  • Biocryst US Sales Co., LLC$95
  • AstraZeneca$90
  • GSK$87
  • Pfizer$46
  • plus $245 from 9 others

What the payments were for

  • Food & beverage$95597%
  • Education$343%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$989 in reported general payments places this provider in the 90th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$12,302
Medicare patients
81
Services billed
798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab106$411,591
TezspireTezepelumab-Ekko50$223,050
CuvitruImmun Glob G(Igg)/Gly/Iga Ov5022$175,760
XolairOmalizumab42$147,464
Fasenra PenBenralizumab22$137,220
Breztri AerosphereBudesonide/Glycopyr/Formoterol65$48,996
DuleraMometasone/Formoterol51$27,638
Spiriva RespimatTiotropium Bromide32$25,517
Advair HfaFluticasone Propion/Salmeterol39$21,518
Breo ElliptaFluticasone/Vilanterol49$19,178
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$16,581
SymbicortBudesonide/Formoterol Fumarate33$13,101
Epinephrine45$11,775
AlvescoCiclesonide12$10,480
Fluticasone-SalmeterolFluticasone Propion/Salmeterol33$7,739

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$90$285,146148 claims
Takeda Pharmaceuticals U.S.A., Inc.Cuvitru$162$175,76022 claims
GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta$87$42,30894 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →